Approved Clinical Trials This page provides a searchable list of all clinical trial research protocols that have been reviewed and approved by the Uganda National Council for Science and Technology (UNCST).
Search By Approval Date:
Clear Filter Total: 339
Name Title Study Sites Nationality Approval Date Expiry Date Sample Size Target Population Sponsors Field of Science/Classification Trial Type Research Type  
EDWARD KIBAYA
ID: UNCST-2025-R019358
 ASSESSMENT PRACTICES AND STUDENTS’ ACADEMIC PERFORMANCE AT UCE IN SELECTED SECONDARY SCHOOLS IN GOMBA DISTRICT, UGANDA.
REFNo: SS4195ES

1. To examine the extent to which Assessment Practices are used by teachers in Selected Secondary Schools in Gomba district. 2. To examine the relationship between Assessment Practices and Student’ Academic Performance at UCE in Selected Secondary Schools in Gomba district. 3. To establish the relationship between Teacher knowledge of Assessment Practices and Students’ Academic Performance at UCE in Selected secondary schools in Gomba district.
Uganda 2026-07-31 9:26:15 2029-07-31 The sample size for the study is 132 respondents selected from 14 secondary schools in Gomba District. It includes 103 classroom teachers (simple random sampling), 14 head teachers, 14 directors of studies, and 1 district inspector of schools (all purposively selected). This sample size aligns with Krejcie and Morgan’s (1970) table for a population of 175, ensuring a 95% confidence level and 5% margin of error. The study population comprises secondary school stakeholders in selected schools within Gomba District, including: Age Group: Primarily adults aged 25–60 years, consisting of teachers, Directors of Studies, Headteachers, and district inspector of schools. Students involved in academic performance analysis will typically be 15–20 years old (UCE candidates). Sex: Both male and female participants will be involved to ensure gender balance. No specific sex is prioritized, and equal opportunity for participation will be observed. Tribe/Ethnic Composition: Gomba District is predominantly inhabited by the Baganda, but other ethnic groups such as Banyankole, Basoga, and Banyarwanda are also present due to internal migration. The study will include participants from these groups where relevant to ensure inclusivity. Other Characteristics: All participants will be literate and directly engaged in the teaching-learning process or educational administration. Their involvement in curriculum delivery or school-level assessment practices makes them suitable for this study. UGANDA UNION SDA CHURCH Social Science and Humanities Clinical Trial Degree Award
Edwin Nuwagira
ID: UNCST-2021-R013488
 Steroids and enhanced spectrum antibiotics for the treatment of patients in Africa with refractory sepsis
REFNo: HS7921ES

The primary objective is:
1) To conduct a randomized 2x2 factorial clinical trial comparing immediate hydrocortisone and enhanced spectrum antimicrobial therapy to standard care for patients with HIV and sepsis in sSA to:
1a) Determine if hydrocortisone decreases 28-day mortality
2a) Determine if expanded spectrum of immediate antimicrobial therapy of rifampin, isoniazid, levofloxacin and linezolid decreases 28-day mortality.
The secondary objectives include:
1) To determine if hydrocortisone plus standard of care decreases the duration of septic shock
2) To determine if the expanded spectrum of antimicrobial therapy plus standard of care improves antibiotic susceptibility
Other secondary objectives include determining if hydrocortisone, the expanded antimicrobial therapy or the combination plus standard of care improve:
• In-hospital mortality
• 6-month mortality
• Time to death
• Duration of hospitalization
• Volume of intravenous fluids received
• Adverse drug events during the 28-day study period
• Time to ambulation
• Time to temperature normalization
• Lactate/delta lactate measurement at randomization and 72 hours from randomization
• Capillary fill time/delta capillary fill time measurement at randomization and 72 hours from randomization
• UVA score at randomization and 72 hours from randomization




 Mbarara, boma
Kabarole, Buhinga
 Uganda 2026-07-31 16:49:15 2029-07-31 172 The study population will consist of adult men and women aged 18 years and above living with HIV who are admitted to Mbarara Regional Referral Hospital and Fort Portal Regional Referral Hospital with sepsis. The study will be open to all eligible adults regardless of sex, tribe, ethnicity, religion, marital status, occupation, or socioeconomic status. Participants will be recruited from the routine patient population served by the participating hospitals in western Uganda. The study population is expected to represent the diverse communities residing within the catchment areas of the participating hospitals, including individuals from different tribal and ethnic backgrounds commonly found in western Uganda. No children or prisoners will be enrolled. Participants with temporary impairment in decision-making capacity due to acute illness may be enrolled through surrogate consent in accordance with ethical and regulatory requirements and re-consented if capacity is regained. Medical and Health Sciences Clinical Trial Non-degree Award
Miriam Nakalembe
ID: UNCST-2021-R014040
 A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY PREGNANT WOMEN AND THEIR INFANTS (BEATRIX)
REFNo: HS8109ES

To describe GBS serotype-specific IgG concentrations measured from dried blood spots in a subset of infant participants at birth; To describe anti-GBS antibodies present in breast milk in a subset of maternal participants vaccinated with GBS6 To describe serum IgG responses to active immunization with diphtheria toxoid�containing vaccine and PCV in infant participants born to maternal participants vaccinated with GBS6 versus placebo. To describe PCV serotype-specific OPA titers after a toddler vaccination in infant participants born to maternal participants vaccinated with GBS6 or placebo. To additionally describe the immune responses to CPS elicited by GBS6 when administered to healthy pregnant women. To describe serum IgG responses to active immunization with diphtheria toxoid� containing vaccine and/or PCV in infant participants born to maternal participants vaccinated with GBS6 versus placebo.,To further describe the immunogenicity of GBS6 in maternal participants when administered to healthy pregnant women. To describe anti-CPS IgG antibody levels predicted to provide protection from invasive GBS EOD and LOD, separately, caused by the 6 individual vaccine serotypes (Ia, Ib, II, III, IV, and V) in infants when GBS6 is administered to healthy pregnant women,To assess the ability of GBS6 to induce opsonophagocytic activity (OPA) titers at birth in infant participants born to maternal participants vaccinated with GBS6,To describe anti-CPS IgG antibody levels in infant participants born to maternal participants vaccinated with GBS6. To describe anti-CPS IgG antibody levels predicted to provide protection from invasive GBS disease (all disease) caused by the 6 individual vaccine serotypes in infants when GBS6 is administered to healthy pregnant women,To evaluate the aggregate predicted VE combining all 6 serotypes in GBS6 to provide protection from invasive GBS EOD based on serotype-specific anti-CPS IgG concentrations measured in infants at birth,To evaluate the aggregate predicted VE combining all 6 serotypes in GBS6 to provide protection from invasive GBS LOD based on serotype-specific anti-CPS IgG concentrations measured in infants at birth. To assess the ability of GBS6 to induce anti-CPS IgG antibody levels predicted to provide protection from invasive GBS early-onset disease (EOD) caused by the 6 individual vaccine serotypes (Ia, Ib, II III, IV, and V) in infants when GBS6 is administered to healthy pregnant women,To assess the ability of GBS6 to induce anti-CPS IgG antibody levels predicted to provide protection from invasive GBS late-onset disease (LOD) caused by the 6 individual vaccine serotypes (Ia, Ib, II III, IV, and V) in infants when GBS6 is administered to healthy pregnant women,To assess the safety of maternal immunization in infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy. To describe the safety and tolerability of GBS6 in maternal participants
 Kampala, Naguru
 Uganda 2026-07-17 17:00:50 2029-07-17 115-150 The study population will include pregnant women attending antenatal services at Naguru General Hospital and their infants after delivery. The study will enroll pregnant women who are healthy participants aged ≤49 years who are between 24 0/7 and 36 0/7 weeks of gestation on the day of planned vaccination and their infants, with an uncomplicated, singleton pregnancy, and who have no known increased risk of pregnancy complications Medical and Health Sciences Clinical Trial Non-degree Award
Abel  Kakuru
ID: UNCST-2022-R009193
 Perennial Malaria Chemoprevention With Dihydroartemisinin-Piperaquine Versus Sulfadoxine-Pyrimethamine Plus Amodiaquine Versus No Chemoprevention: A Double Blind Randomised Controlled Trial
REFNo: HS7437ES

1. To compare the protective efficacy of combining R21 vaccination with PMC-DP or PMC-SPAQ vs R21 alone up to 5 years of age.
2. To compare the safety and tolerability of combining R21 vaccination with PMC-DP vs. PMC-SPAQ.
3. To determine the impact of PMC on the drug resistance landscape and R21-specific immunogenicity and durability.

 Busia, TC
 Uganda 2026-07-16 20:29:47 2029-07-16 1290 HIV-uninfected infants HIV-uninfected infants DMID Funding Medical and Health Sciences Clinical Trial Non-degree Award
Isaac Ssinabulya
ID: UNCST-2021-R004352
 An mHealth implementation strategy to address the syndemic of mental illness, hypertension, and HIV in Uganda. Clinical Trial: Syndemic Adapted Medly Uganda (SAMU)
REFNo: HS7936ES

To evaluate the factors impacting sustained engagement in the adapted Medly Uganda,To assess the effectiveness of the Syndemic-Adapted Medly Uganda (SAMU) to improve mental health care cascade metrics. ,
 Kampala, Naguru
 Uganda 2026-07-16 19:31:27 2029-07-16 1500 The study population consists of patients who are 18 years and above, that are living with HIV and receiving ongoing care at one of the 3 participating sites in this research (n=1500). A subset of this population who also have hypertension will be enrolled in a longitudinal cohort (n=210). It is estimated that up to 25% of patients living with HIV have hypertension, so this is an achievable sample. We’ll also conduct qualitative interviews with healthcare workers and study participants in the intervention arm at the end of the trial. Medical and Health Sciences Clinical Trial Non-degree Award
Musa Sekikubo
ID: UNCST-2021-R014010
 A phase 3, randomized, placebo-controlled, double-blinded trial to evaluate the safety, tolerability, and immunogenicity of a multivalent Group B Streptococcus vaccine in healthy pregnant women and their infants.
REFNo: HS8122ES

To evaluate the aggregate predicted VE combining all 6 serotypes in GBS6 to provide protection from invasive GBS EOD based on serotype-specific anti-CPS IgG concentrations measured in infants at birth,To evaluate the aggregate predicted VE combining all 6 serotypes in GBS6 to provide protection from invasive GBS LOD based on serotype-specific anti-CPS IgG concentrations measured in infants at birth.,To assess the ability of GBS6 to induce anti-CPS IgG antibody levels predicted to provide protection from invasive GBS early-onset disease (EOD) caused by the 6 individual vaccine serotypes (Ia, Ib, II III, IV, and V) in infants when GBS6 is administered to healthy pregnant women.,To assess the ability of GBS6 to induce anti-CPS IgG antibody levels predicted to provide protection from invasive GBS late-onset disease (LOD) caused by the 6 individual vaccine serotypes (Ia, Ib, II III, IV, and V) in infants when GBS6 is administered to healthy pregnant women.,To assess the safety of maternal immunization in infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy.,To describe the safety and tolerability of GBS6 in maternal participants,
 Kampala, Kawempe
Uganda 2026-07-16 19:21:43 2029-07-16 150 Pregnant women aged 18 years and above in their 3rd trimester Medical and Health Sciences Clinical Trial Non-degree Award
Cristina Reverzani
ID: UNCST-2023-R008154
 Vitamin D supplementation among pregnant women in Uganda for the prevention of adverse obstetric outcomes: a randomized controlled trial
REFNo: HS7794ES

The objective of this trial is to investigate if vitamin D supplementation among pregnant women in Uganda prevents adverse maternal and foetal outcomes, with special emphasis on preeclampsia.
Italy 2026-06-25 22:39:41 2029-06-25 - Intervention group – 990 women will receive oral 2.000 IU vitamin D daily; or. - Control group – 990 women will receive an oral placebo daily. The target population of the present study will comprise pregnant women, attending ANC services in the gestational week from 13 to 27, who meet the eligibility criteria. The accessible population of the present study will comprise all the women attending ANC at Lacor Hospital during the study period, who meet the eligibility criteria. Pregnant women, attending ANC services in the gestational week from 13 to 27, confirmed by ultrasonography, will receive oral and written information about the trial by a member of the research group, and will be invited to participate in the trial. Those who agree to participate will give informed consent, in agreement with the Declaration of Helsinki. The study population of the present research will not include special or vulnerable subjects such as minors, prisoners and mentally handicapped subjects. Medical and Health Sciences Clinical Trial Non-degree Award
Pauline Byakika-Kibwika
ID: UNCST-2019-R001206
 Platform Adaptive Randomised Trial for NEw and Repurposed Filovirus treatmentS
REFNo: HS7849ES

To evaluate the impact of potential treatments on mortality in patients with filovirus disease. ,
 Uganda 2026-06-08 21:31:41 2029-06-08 0 All patients with Ebola, all age, all sex is included Medical and Health Sciences Clinical Trial Non-degree Award
NSUBUGA GERALD
ID: UNCST-2021-R011633
 Feasibility and Acceptability Using Umbilical Cord Blood for Cancer Treatment through Stem Cell Transplantation: A Multi-Center Study Involving Pregnant Mothers, Health Workers, and Cancer Patients in Collaboration with the Uganda Blood Transfusion Service
REFNo: HS6131ES

General Objective To assess the feasibility and acceptability of collecting and using umbilical cord blood for stem cell transplantation in cancer patients based on the perceptions and readiness of pregnant mothers, health professionals, and cancer patients in selected public health facilities in Uganda. Specific Objectives 1. To determine the level of awareness and knowledge about umbilical cord blood stem cell transplantation among pregnant mothers, health professionals, and cancer patients. 2. To assess the willingness of pregnant mothers to donate umbilical cord blood for therapeutic use. 3. To evaluate the preparedness of health professionals to support UCB collection, processing, and utilization.
Kampala,
Wakiso,
Uganda 2026-06-05 15:35:56 2029-06-05 385 The study population will comprise diverse groups of individuals relevant to the establishment of an umbilical cord blood bank for allogeneic stem cell transplantation at Uganda Blood Transfusion Service (UBTS). Expectant Mothers: Pregnant women aged 18 to 45 years attending antenatal clinics at selected hospitals will form the primary group. This age range represents women of reproductive age with the potential to donate umbilical cord blood. Expectant mothers from different tribes and ethnic backgrounds across Uganda will be included to ensure diversity and representativeness. Healthcare Providers: Participants will include medical doctors, nurses, midwives, and laboratory personnel involved in maternal and child health, blood banking, and oncology services. Their insights will be critical in understanding technical and operational needs. Both male and female providers will be included, with no age restrictions, focusing on those actively working in relevant departments. UBTS Staff and Policymakers: Staff from UBTS, including management and technical personnel, as well as policymakers from the Ministry of Health, will participate to provide perspectives on regulatory, logistical, and financial requirements. Community Representatives: Community leaders and opinion leaders from various regions and ethnic groups will also be engaged to capture cultural attitudes and perceptions about umbilical cord blood donation. Government of Uganda Medical and Health Sciences Clinical Trial Non-degree Award
Namulema Edith
ID:
Exploring the feasibility and safety of using the ‘LeVe Neonatal CPAP System’ to assist neonates with signs of respiratory distress at Mengo Hospital
REFNo: HS7747ES

1) Feasibility Objective - To determine the proportion of neonates in whom the LeVe CPAP device can be successfully initiated and maintained for the entire study duration.
2) Safety Objective - To determine the incidence of CPAP-related adverse events occurring within the first 7 days of CPAP therapy.
3) Respiratory Effectiveness Objective - To assess the early respiratory response to CPAP within 2 hours of initiation and for the entire study duration using SpO?, FiO? measures and the Silverman-Andersen respiratory distress score.
4) Prematurity-Related Outcome Objective - To determine the incidence of survival to discharge, bronchopulmonary dysplasia, and retinopathy of prematurity.
5) To explore healthcare workers' perceptions and experiences regarding CPAP training adequacy, their confidence in using neonatal CPAP, and their views on how CPAP implementation influences neonatal respiratory outcomes within their clinical setting

 Kampala, Mengo
 Uganda 2026-05-28 16:35:26 2029-05-28 40 Neonates Age: 0–28 days of life. University of Leeds Medical and Health Sciences Clinical Trial Non-degree Award
Henry Mugerwa
ID: UNCST-2019-R000420
 A Phase I/II clinical study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ITU512 in healthy participants and patients with sickle cell disease
REFNo: HS6925ES

1.To assess the safety and tolerability
of ITU512 in healthy participants
2.To assess the safety and tolerability
of ITU512 in participants with SCD
3.To assess the effect of ITU512 on
fetal hemoglobin expression

 Wakiso, Sabagabo
 Uganda 2026-05-22 16:52:18 2029-05-22 89 children, adults, mela and female Norvatis Medical and Health Sciences Clinical Trial Non-degree Award
Elizabeth Kaudha
ID: UNCST-2025-R017151
 A Phase 3b, open-label, multicenter, continued access study for participants transitioning from ViiV Healthcare-sponsored or ViiV Healthcare collaborative parent studies for HIV treatment.
REFNo: HS7588ES

The main objective of the study is to provide continued access to study interventions for participants who were enrolled and treated in ViiV Healthcare-sponsored or ViiV Healthcare-collaborative parent studies and who continue to experience clinical benefit, and to describe the continued use and safety of the study intervention. The specific objectives of this study are, Reasons for discontinuation of study intervention Incidence and outcome of serious adverse events (SAEs) Incidence and outcome of adverse events of special interest (AESIs)
 Kampala, Mulago II Parish
Wakiso, Lubowa Parish
Kampala, Kansanga parish
 Uganda 2026-05-15 18:55:49 2029-05-15 130 Participants eligible for this study are individuals with HIV-1 who received the study intervention and completed the protocol-defined treatment period in ViiV Healthcare-sponsored or ViiV Healthcare-collaborative parent studies, and who, at the time of transition to this continued access study, experience clinical benefit as determined by the Investigator of Record from the parent study intervention ViiV Healthcare UK Limited, 79 New Oxford Street, London, WC1A 1DG, United Kingdom Medical and Health Sciences Clinical Trial Non-degree Award
Francis Ssali
ID: UNCST-2021-R012134
 A5424 Menopausal Hormone Therapy for Women Living with HIV (HoT)
REFNo: HS7391ES


1.2 Primary Objective

1.2.1 Determine the effects of HT on VMS in WLWH in the late menopausal transition or early postmenopause.

1.3 Secondary Objectives

1.3.1 Evaluate the safety and tolerability of HT as compared to placebo.

1.3.2 Determine the effect of HT on neurocognition.

1.3.3 Determine the effect of HT on mood.

1.3.4 Determine the effect of HT on sleep.

1.3.5 Determine the effect of HT on quality of life.

1.3.6 Determine the effect of HT on sexual function.

1.3.7 Determine the effect of HT on weight, waist circumference, and waist-to-hip ratio.

1.4 Exploratory Objectives

1.4.1 Determine the effect of HT on markers of bone turnover.

1.4.2 Determine the effect of HT on markers of cardiometabolic health.

1.4.3 Determine the effect of HT on systemic markers of inflammation and immune activation.

1.4.4 Determine the effect of HT on HIV reservoir size, clonality, and activity.

1.4.5 Determine the effect of HT on measures of physical function.

1.4.6 Determine the effect of HT on the rectal and vaginal microbiome.

1.4.7 Explore the effect of HT on all primary and secondary outcomes by antiretroviral regimen.

1.4.8 Explore exposure-response relationships between estradiol pharmacokinetics (PK) and study outcomes in those treated with estradiol.

1.4.9 Evaluate acceptability and feasibility of ambulatory monitors for VMS and sleep on a subset of participants.

1.4.10 Explore agreement between subjective VMS frequency with objective VMS frequency in a subset of participants.


 Kampala, Seguku
 Uganda 2026-04-24 13:20:15 2029-04-24 96 40-60 YEARS OLD WOMEN LIVING WITH HIV/AIDS. ENGLISH AND LUGANDA UNDERSTANDING PARTICIPANTS National Institute of Allergy and Infectious Diseases Medical and Health Sciences Clinical Trial Non-degree Award
Yudaya Nakyeyune
ID: UNCST-2026-R024597
 Using Play in Culturally Responsive Ways to Enhance Children’s Numeracy Skills Achievement in Refugee-Hosting ECD Centers in Kampala
REFNo: SS5116ES

1. To analyze children's voices of learning through play in refugee hosting ECD centers in Kampala.
2. To identify the challenges teachers encounter when using play in the teaching of numeracy in refugee hosting ECD centers in Kampala
3 To establish the impact of engagement in Continuing Professional Development (CPD) on teachers' knowledge regarding the use of play-based methods in culturally responsive ways in refugee hosting ECD centers in Kampala
4. To assess the impact of engagement in culturally responsive learning through play activities on children's numeracy achievement in refugee hosting ECD venters in Kampala
Kampala, Makerere
 Uganda 2026-04-20 16:47:28 2029-04-20 264 The study sample will consist of eight centers, 24 teachers (three per center), and 480 children (60 per center; 240 children in each arm). Within each center, three P1–P3 classes, each with approximately 20 children, participate. Randomization will be stratified based on center characteristics, specifically the proportion of refugee children (high or low), and will be conducted using computer-generated random numbers. Self Sponsored Social Science and Humanities Clinical Trial Degree Award
Fred Kigozi
ID: UNCST-2025-R021423
 Postprandial effect of isocaloric challenge meals enriched with indigenous fruits and vegetables on glucose metabolism in individuals with type 2 diabetes in Wakiso District, Uganda.
REFNo: HS7347ES

General Objective To evaluate the postprandial effect of isocaloric challenge meals enriched with indigenous fruits and vegetables on glucose metabolism among people living with type 2 diabetes in Wakiso district, Uganda. Specific Objectives 1.To assess the acute postprandial effects of isocaloric challenge meals enriched with indigenous fruits and vegetables on incremental area under the curve (iAUC) blood glucose levels. 2.To assess the acute postprandial effects of isocaloric challenge meals enriched with indigenous fruits and vegetables on iAUC blood triglyceride levels.
Wakiso, Kitende
 Uganda 2026-04-20 10:47:24 2029-04-20 8 People living with type 2 diabetes aged 30-60 years 1 Medical and Health Sciences Clinical Trial Degree Award
William Worodria Ofuti
ID: UNCST-2022-R010915
 Program for Rifampicin-Resistant Disease with Stratified Medicine for TB” (PRISM-TB)
REFNo: HS7398ES

To identify, among participants with fluoroquinolone-susceptible multidrug-resistant/rifampicin-resistant tuberculosis (FQ-S MDR/RR-TB), the preferred BPaLM strategy of 13 or 17 weeks for participants stratified to receive shorter treatment and 17 or 24 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, and to evaluate whether this BPaLM strategy has noninferior efficacy to the control strategy at Week 73.

1. To evaluate whether a BPaLM strategy of 17 weeks for participants stratified to receive shorter treatment and 24 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, has superior DOOR probability to the control strategy combining efficacy at the end of follow-up (a minimum of 28 weeks post-randomization) and safety at 28 weeks post-randomization.
2. To evaluate whether a BPaLM strategy of 17 weeks for all participants has superior DOOR probability to the control strategy combining efficacy at the end of follow-up (a minimum of 28 weeks post-randomization) and safety at 28 weeks post-randomization.
3. To evaluate whether a BPaLM strategy of 13 weeks for participants stratified to receive shorter treatment and 24 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, has superior DOOR probability to the control strategy combining efficacy at the end of follow-up (a minimum of 28 weeks post-randomization) and safety at 28 weeks post-randomization.
4. To evaluate whether a BPaLM strategy of 13 weeks for participants stratified to receive shorter treatment and 17 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, has superior DOOR probability to the control strategy combining efficacy at the end of follow-up (a minimum of 28 weeks post-randomization) and safety at 28 weeks post-randomization.
5. To compare the proportion of participants who experience grade 3 or higher adverse events by Week 28 in the preferred BPaLM strategy to the control strategy.
6. To compare the proportion of participants who experience adverse events of special interest by Week 28 in the preferred BPaLM strategy to the control strategy.
7. To compare the proportion of participants who experience a TB-related unfavorable outcome at Week 73 on the preferred BPaLM strategy with the control strategy, among participants stratified to receive shorter treatment.
8. To compare the proportion of participants who experience a TB-related unfavorable outcome at Week 73 on the preferred BPaLM strategy with the control strategy, among participants stratified to receive longer treatment.
9. To evaluate the pharmacokinetics of all drugs in the BPaLM regimen with an additional focus on bedaquiline elimination (Stages 1 and 2).
10. To determine the dose-response and exposure-response relationships between study drug estimated PK parameters with efficacy and toxicity (Stages 1 and 2).
11. To evaluate the feasibility and acceptability of treatment stratification in the context of treatment for MDR/RR-TB from the participant and the health system perspective (Stages 1 and 2).
 Kampala,
Uganda 2026-04-10 18:15:27 2029-04-10 60 All SMART TB Medical and Health Sciences Clinical Trial Non-degree Award
Richard Idro
ID: UNCST-2021-R013599
 Dihydroartemisinin-piperaquine for the post-discharge management of children with severe acute malnutrition in Malawi and Uganda; A multicentre, parallel-group, two-arm, randomised, double-blind superiority trial [Short Title: Post-discharge Malaria Chemoprevention - SAM (PDMC-SAM)]
REFNo: HS7291ES

To determine if 4 months of PDMC with dihydroartemisinin piperaquine (DP) compared to placebo is superior in reducing hospital readmissions and death by 6 months in children aged <5 years admitted with ‘SAM’ who are clinically stable and ready to be discharged to OTC.,
 Jinja, Nalufenya
 Uganda 2026-04-10 18:06:21 2029-04-10 Overall 560, about 300 in Uganda Children, aged <5 years, with severe acute malnutrition [defined as weight-for-height <-3 SD-score or mid-upper circumference <115 mm, or symmetrical pitting oedema], discharged through/attending Outpatient Therapeutic care (OTC) clinics. Training and Research Unit of Excellence, Blantyre, Malawi Medical and Health Sciences Clinical Trial Non-degree Award
Waiswa Peter
ID: UNCST-2020-R014921
 An effectiveness-implementation trial of a peer mentorship intervention to help women navigate barriers to contraceptive use in rural Uganda
REFNo: HS7355ES

Main objective
: Our main aim is to increase women’s ability to overcome barriers to contraceptive use and to support adoption of self-injectable contraception. After promising findings in our pilot study, we propose to build on our strong, ongoing partnership between Makerere University in Uganda and the University of California, San Francisco to test “I-CAN” intervention on a larger scale.
Objectives
1. To test the effectiveness of a peer mentorship intervention on contraceptive use and contraceptive self-injection (Aim 1).
2. To examine the process of implementing I-CAN intervention; the ICAN’s reach to mentees, differential effectiveness, adoption and maintenance by mentors, implementation fidelity and innovations, and contextual factors (Aim 2)
3. To examine the cost-effectiveness of the peer mentorship intervention versus standard of care (counselling by health facility or community health workers) in supporting contraceptive use and contraceptive self-injection (Aim 3).

Iganga, Yet to be selectedYet to be selecetd
Kole, Yet to be selecetd
 Uganda 2026-04-02 12:45:33 2029-04-02 The trial is powered for all outcomes. 26 villages per arm (52 total clusters) with a cluster size of 30 households (total N=1,560 households at each timepoint) will allow us ?80% power (alpha=0.05) to detect the following effect sizes among women ages 18-49 between arms at 24- months: The primary study population will include women ages 18-49 years form Iganga and Kole districts; Basoga nd langi tribes National Institutes for Health Medical and Health Sciences Clinical Trial Non-degree Award
Victoria Ndyanabangi
ID: UNCST-2021-R012645
 IMPAACT 2024- Protocol Titled: Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. DAIDS Study ID #38747,IND #171439
REFNo: HS6638ES

To determine weight-band dosing of a once-daily, 28-day regimen of isoniazid (INH) and rifapentine (RPT) (1HP) for the prevention of tuberculosis (TB) in children living with and without HIV.

Primary Objectives
Cohort 1 and Cohort 2
To determine the weight-band dosing of RPT taken as part of the 1HP regimen by evaluating:
? PK RPT exposures among children with and without HIV
? Safety and tolerability of the 1HP regimen among children with HIV while receiving twice-daily
DTG and children without HIV through 28 days of dosing

Cohort 2
• To evaluate the effect of RPT taken as part of the 1HP regimen on the PK of DTG
Secondary Objectives
Cohort 1 and Cohort 2
To evaluate the effect of covariates including age, weight, sex, ethnicity, nutritional status, and HIV-1 status on the PK of RPT taken as part of the 1HP regimen
• To evaluate the safety of the 1HP regimen through 24 weeks of follow-up
• To evaluate the palatability and acceptability of the 1HP regimen
• To evaluate adherence to the 1HP regimen

Cohort 2
• To evaluate the safety and tolerability of twice-daily DTG through 42 days among children with HIV who are receiving 1HP
• To evaluate virologic control (less than 200 copies/mL) at Day 42 among children taking a DTG-Based ARV treatment regimen co-administered with 1HP

Kampala, All Parishes
 Uganda 2026-03-30 12:54:54 2029-03-30 48 Children living without HIV (Cohort 1) and children living with HIV (Cohort 2) at risk of TB disease who are less than 13 years of age. Children in Cohort 2 will receive an antiretroviral (ARV) treatment regimen containing dolutegravir (DTG). National Institute of Allergy and Infectious Diseases Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institute of Mental Health Medical and Health Sciences Clinical Trial Non-degree Award
Monicah Agaba
ID: UNCST-2024-R004221
 The effect of a peer modelled complex behavioural change intervention on the cardio-metabolic health of women in Mbarara City, Uganda
REFNo: HS7211ES

1. To assess the effect of the a complex behavioural change intervention on the central adiposity of the WRA.,To evaluate the overall effectiveness of a peer modelled complex behavioural change intervention on the cardio-metabolic health of women through a cluster randomised control trial.,
 Mbarara, Kakoba
 Uganda 2026-03-25 10:44:24 2029-03-25 157 18 to 49 years Women of reproductive age All tribes Residents of Kakoba Ward within Mbarara City Katholieke Universiteit Leuven Medical and Health Sciences Clinical Trial Degree Award
Abdul Malik Muwanga
ID: UNCST-2026-R024094
 Developing Leadership Skills of ECCE Center Management Committees in Palorinya Refugee Hosting ECCE centers - Obongi District
REFNo: SS5010ES

1 Identify gaps in the leadership skills of CMCs in refugee hosting ECCEcenters in Palorinya refugee settlement.
2 Develop a training program to strengtheb the leadership skills of CMCs in enhancing children’s learning outcomes in Palorinya refugee settlement.
3 Implement a training program to develop the leadership skills of CMCs to improve children’s learning outcomes in refugee-hosting ECCE centers in Palorinya.
4 Evaluate the effectiveness of a training program in developing the leadership skills of ECCECenter Management Committees to improve children’s learning outcomes in Palorinya refugee settlement.
5 Generate principles to guide the development and implementation of training programs for developing the leadership skills of CMCs to improve children’s Early Learning Outcomes (ELOs) in ECCEcenters in related poly-crisis contexts.

 Moyo, Palorinya
 Uganda 2026-03-24 8:59:47 2029-03-24 90 90 participants drawn from 10 Early Childhood Care and Education (ECCE) centers located within Palorinya Refugee Settlement, encompassing a range of institutional types 3 supported by UNHCR, 2 by Save the Children International, and 5 community-managed (ChildFund Alliance, 2022). Self Sponsored Social Science and Humanities Clinical Trial Degree Award
Dennis Muhanguzi
ID: UNCST-2019-R001101
 Evaluation of The Safety, Efficacy and Stability of SangaDelta® Emulsifiable Concentrate [E.C]: A Randomised Single-Blinded Positive Controlled Multi-Site Acaricide Field Trial
REFNo: NS1194ES

General objectives
To determine the efficacy, safety, and stability of SangaDelta® (Sanga Vet. Chem. Ltd, Kampala Industrial Park, Namanve ) when applied onto cattle by hand spraying and plunge dipping for tick control.

Specific objectives
The specific objectives of this acaricide field trial will to determine:
i.Efficacy of SangaDelta® when applied onto cattle by hand spraying and plunge dipping for tick control.
ii.Safety of SangaDelta® when applied onto cattle by hand spraying and plunge dipping for tick control.
iii.Stability of SangaDelta® when applied onto cattle by plunge dipping for tick control.

Mayuge, Lwanika
Mayuge, Buyemba
Mayuge, Lukone
Kumi, Boma
Serere, Okidi
Serere, Akumoi
Uganda 2026-03-19 16:13:37 2029-03-19 500 cattle above 3 months of age of box sexes and all breeds at the six participating farms The study population will constitute cattle of any breed owned by 6 participating farmers in Mayuge [3 farmers], Kumi [one Farmer] and Serere [2 Farmers] district. A total of 500 cattle above 3 months of age will be recruited. Both female, male and neutered cattle will be enrolled into the study Sanga Vet. Chem. Ltd P.O Box 75164 | Plot 1144, Kampala Industrial Business Park | Kampala-Uganda Tel: 02008000100 | Web: https://www.sangavetchem.com/ Natural Sciences Clinical Trial Non-degree Award
Adoke Yeka
ID: UNCST-2021-R004300
 A Phase 2A study to evaluate the safety, tolerability and pharmacokinetics of a novel antimalarial pyrrolidinamide at different doses and dose durations, in adult patients with uncomplicated P. falciparum malaria
REFNo: HS7237ES

Primary objective:
To investigate the safety and tolerability of GSK3772701 after single and repeat oral doses in adult patients with uncomplicated P. falciparum malaria.
Secondary objectives
To evaluate the PK profile of single and repeat oral doses of GSK3772701 in adult patients with
uncomplicated P. falciparum malaria.

Exploratory objectives.
1. To evaluate the efficacy of single and repeat oral doses of GSK3772701 in adult patients with uncomplicated P. falciparum malaria.
2. To characterize the PK/PD relationship.
3. To evaluate P. falciparum genetic polymorphisms and potency of GSK3772701.
4. To assess the safety of GSK3772701 for individual parameters after single and repeat oral doses in adult patients with uncomplicated P. falciparum malaria

 Tororo, Whole district
 Uganda 2026-03-19 16:01:49 2029-03-19 A total of approximately 70 adult patients, with uncomplicated P. falciparum mono-infection, will be enrolled into the study across 5 cohorts Male and female patients aged 18 to 65 years. GlaxoSmithKline Research & Development Limited, 79 New Oxford Street, London WC1A 1DG, United Kingdom. Medical and Health Sciences Clinical Trial Non-degree Award
Dennis Muhanguzi
ID: UNCST-2019-R001101
 Evaluation of The Safety, Efficacy and Stability of Sangaphos® Emulsifiable Concentrate [E.C]: A Randomised Single-Blinded Positive Controlled Multi-Site Acaricide Field Trial
REFNo: NS1171ES

General objectives: To determine the efficacy, safety, and stability of SangaPhos [Sanga Vet. Chem. Ltd, Kampala Industrial Park, Namanve] when applied onto cattle by hand spraying and plunge dipping for tick control. Specific objectives The specific objectives of this acaricide field trial will to determine; i.Efficacy of Sangaphos® when applied onto cattle by hand spraying and plunge dipping for tick control. ii.Safety of Sangaphos® when applied onto cattle by hand spraying and plunge dipping for tick control. iii.Stability of Sangaphos® when applied onto cattle by plunge dipping for tick control.
Kyenjojo, Ntuutu
Kyenjojo, Bwenzi
Kyenjojo, Hima
Serere, Aarapoo
Serere, Aswii
Kumi, Kachaboi
Uganda 2026-03-03 12:23:56 2029-03-03 633 Six Cattle farms from Kyenjojo [n=3], Kumi [n=01] and Serere each with at least 66 cattle will be recruited. Total number of cattle at the six farms = 633. The animals will be at least 2 months of age. Both sexes and any cattle breeds on these farms will be recruited. Sanga Vet. Chem. Ltd P.O Box 75164 | Plot 1144, Kampala Industrial Business Park | Kampala-Uganda Tel: 02008000100 | Web: https://www.sangavetchem.com/ Natural Sciences Clinical Trial Non-degree Award
Susan  Nabadda Ndidde
ID: UNCST-2020-R014331
 CLINICAL PERFORMANCE EVALUATION (RETROSPECTIVE STUDY) OF THE STANDARD Q HIV/SYPHILIS/HBsAg TRIPLE TEST
REFNo: HS6651ES

Quantify the proportion of uninterpretable (Invalid) results to gauge operational feasibility based on the invalid rate.,Assess Inter-reader Variability among different operators to ensure consistency in test interpretation and hence reliability in real-world settings.,To assess the diagnostic accuracy of the STANDARD Q HIV/Syphilis/HBsAg Triple Test, a rapid chromatographic immunoassay for simultaneous detection of HIV-1/2 antibodies, syphilis (Treponema pallidum) antibodies, and hepatitis B surface antigen (HBsAg). ,
 Kampala, National Health Laboratory and Diagnostic Service, Ministry of Health
 Uganda 2026-02-12 13:03:06 2029-02-12 Sample sizes for each disease analyte are calculated to achieve 95% confidence intervals with ±5% margin of error for sensitivity/specificity estimates. Clinical performance will follow the WHO TSS-1, TSS-6 and TSS-13 which require a sample size of up to 1000 samples; to achieve a pre-test clinical performance assessment of the HIV/Syphilis/HBsAg rapid diagnostic test kit, 50 samples of each disease analyte category will be used. Stored samples for 18 years and above for both males and females for all tribes will be considered. This retrospective study shall use archived samples from the CPHL biorepository with proof that at the time of sample collection, the source of the selected sample signed a broad consent indicating acceptance of storage for future research use of the remnant of their collected sample. Samples shall be selected from already known specific disease-characterized sets of positive and negative HIV, Syphilis and HBsAg. Department of National Health Laboratory and Diagnostic Service, Ministry of Health Medical and Health Sciences Clinical Trial Non-degree Award
Pauline Amuge Mary
ID: UNCST-2023-R005532
 Bedaquiline Roll-out Evidence in Contacts and People Living with HIV to prevent TB (BREACH-TB)
REFNo: HS6975ES

2.1.1.To estimate the safety of 1BDQ and 3HP among
adult, adolescent, and child CCs of DS-TB Index
Patients at high risk of developing TBD, as well
as adult and adolescent PLHIV in high TB burden settings

2.1.2To estimate the safety of 1BDQ and 6 months of
levofloxacin (LFX) among adult, adolescent, and
child CCs of RR-TB Index Patients at high risk of
developing TBD
2.1.3 To estimate on-time treatment completion of
1BDQ and 3HP among adult, adolescent, and
child CCs of DS-TB Index Patients at high risk of
developing TBD, as well as adult and adolescent
PLHIV in high TB-burden settings
2.1.4To estimate on-time treatment completion of
1BDQ and 6 months of levofloxacin (LFX)
among adult, adolescent, and child CCs of RRTB Index Patients at high risk of developing TBD
 Wakiso, Ssabagabo
 Uganda 2026-02-05 22:05:22 2029-02-05 3130 High-risk close contacts (CC) of an individual diagnosed with DS- or RR-TBD (i.e., the Index Patient) and PLHIV in high-TB burden regions United States Agency for International Development Medical and Health Sciences Clinical Trial Non-degree Award
AGNES NAGGIRINYA BWANIKA
ID: UNCST-2019-R001126
 Evaluating the impact on 90-day survival of post-discharge follow-up strategies delivered to adult patients hospitalized with sepsis across a research network in sub-Saharan Africa [Call for Life – Sepsis (C4L-Sepsis)]
REFNo: HS6882ES

To compare baseline demographic and clinical characteristics between participants who were randomized and those who did not meet randomization criteria (screen failures),To evaluate participant quality of life at 28- and 90-days post discharge period within two study arms.,To evaluate the proportion of participants within the two study arms who require re-admission to hospital during the post-discharge period of 90 days,To evaluate proportion of participants within the two study arms who return for scheduled post discharge follow-up visits ,To evaluate the efficacy on 28-day mortality among participants hospitalized with sepsis randomized to receive one of two post discharge follow-up strategies – EDI versus EDI plus IVR tool,To evaluate the efficacy on 90-day post-discharge mortality among adult participants hospitalized with sepsis randomized to receive one of two post discharge follow-up strategies – EDI versus EDI plus IVR tool,III. To train clinical officers about vitamin D and its application in managing the co-morbidity illnesses under study. This involves training and mentoring of clinical officers so as to acquire knowledge about vitamin D especially in relation to its clinical effects and treatment of malaria, diabetes, HTN, UTIs, and post covid-19 syndrome. This will enable build enough human capacity and willingness to carry out more research about vitamin D.,To develop prototypes of the efficacy doses of vitamin D for each co- morbidity group. From objective II, the efficacy doses (values) of vitamin D will be recorded. Vitamin D prototypes containing different formulations for each co-morbidity illness will be developed. These will be in form of; solutions, powder and inhalers,To establish the efficacy of vitamin D to the co-morbidity illnesses. This involves giving different doses of vitamin D to study participants in each co- morbidity group in addition to the illness’ conventional drugs while monitoring for change using the monitors of change tests/investigations to ascertain these therapeutic effects of Vitamin D.,To develop prototypes of the efficacy doses of vitamin D for each co-morbidity group. ,To explore vitamin D’s therapeutic efficacy to the co-morbidity diseases (malaria, HTN, diabetes, UTIs and post covid-19 syndrome) under study,III. To train clinical officers about vitamin D and its application in managing the co-morbidity illnesses under study. ,II. To develop prototypes of the efficacy doses of vitamin D for each co-morbidity group,I. To establish the efficacy of vitamin D to the co-morbidity illnesses,To explore vitamin D’s therapeutic efficacy to the co-morbidity diseases (malaria, HTN, diabetes, UTIs and post covid-19 syndrome) under study. ,III. To train clinical officers about vitamin D and its application in managing the co-morbidity illnesses under study. This involves training and mentoring of clinical officers so as to acquire knowledge about vitamin D especially in relation to its clinical effects and treatment of malaria, diabetes, HTN, UTIs, and post covid-19 syndrome. This will enable build enough human capacity and willingness to carry out more research about vitamin D,II. To develop prototypes of the efficacy doses of vitamin D for each co-morbidity group. From objective II, the efficacy doses (values) of vitamin D will be recorded. Vitamin D prototypes containing different formulations for each co-morbidity illness will be developed. These will be in form of; solutions, powder and inhalers ,I. To establish the efficacy of vitamin D to the co-morbidity illnesses. This involves giving different doses of vitamin D to study participants in each co-morbidity group in addition to the illness’ conventional drugs while monitoring for change using the monitors of change tests/investigations to ascertain these therapeutic effects of Vitamin D.,To explore vitamin D’s therapeutic efficacy to the co-morbidity diseases (malaria, HTN, diabetes, UTIs and post covid-19 syndrome) under study. This will be achieved by clinical application of vitamin D, assessing and monitoring its effect in the treatment of the respective comorbidity illness as well as developing of different formulations of vitamin D that had effect in each co-morbidity group. ,
 Masaka, Kimanya
Kampala, Mulago 1
 Uganda 2026-01-30 19:36:32 2029-01-30 353 Male and Female adults ≥18 years of all tribes who can understand English and Luganda. Stephen Okoboi Medical and Health Sciences Clinical Trial Non-degree Award
Isabelle Cohen
ID: UNCST-2025-R020977
 Evaluating a “nearly free hour” for health centers in rural Uganda
REFNo: SS4726ES

This study has four specific objectives: 1. Evaluate the effects of a discounted, group visits window on ODH health centers, including how many ultrapoor patients visit the clinic during the discounted, group visits window. 2. Compare the discounted window to an all-day discount to understand whether a time-limited discount is (relatively) more effective at screening in the UP. 3. Document the extent to which the discounted window cannibalizes revenue by shifting patients from other times of day to the discounted window. 4. Analyze whether discounts encourage earlier treatment for mild/moderate malaria, and correspondingly reduce visits for severe malaria.
USA 2026-01-27 19:41:22 2029-01-27 25000 The total set of districts includes ADJUMANI, AGAGO, ALEBTONG, AMOLATAR, AMURIA, AMURU, APAC, DOKOLO, GULU, KADERAMAIDO, KAGADI, KAKUMIRO, KASSANDA, KATAKWI, KIBAALE, KIKUUBE, KITGUM, KOLE, KUMI, KWANIA, LIRA, MASINDI, MUBENDE, NWOYA, OMORO, OTUKE, OYAM, PADER and SERERE. The study sample focuses on villages in the catchment areas of existing ODH health clinics. We include villages that are not health clinic locations, from which more than a minimum number of patients visit ODH health clinics in an average week. We expect to sample roughly six villages per health clinic. All patients from a participating village who visit an ODH clinic included in the study will be considered part of the study. Weiss Fund for Research in Development Economics, Princeton University’s Research Program in Development Economics and OneDay Health Social Science and Humanities Clinical Trial Non-degree Award
Adeodata Rukyalekere Kekitiinwa
ID: UNCST-2019-R000799
 Long-Acting Treatment in Adolescents (LATA); A randomized open-label 2-arm 96-week trial in virologically suppressed HIV-1-positive adolescents aged 12-19 years of age in Sub-Saharan Africa version 1.0 dated 01 December 2021.
REFNo: HS2515ES

• To evaluate an innovative and contemporary ART strategy in HIV- positive adolescents to provide choice for young people facing life-long treatment.
• To evaluate the virological efficacy, safety, acceptability, and quality-of-life of the dual long-acting injectable combination, cabotegravir and rilpivirine, antiretroviral therapy compared to continuous daily oral therapy with triple oral ART consisting of DTG with a backbone of tenofovir either as the TAF or TDF formulations, combined with either 3TC or FTC regimen, to optimize treatment for HIV-positive adolescents in sub-Saharan Africa.

 Kampala, Mulago
 Uganda 2026-01-27 19:28:37 2029-01-27 170 Adolescents aged 12 to 19 years of age living with HIV-1 who are not pregnant or breastfeeding, and are virologically-suppressed (HIV-1 RNA <50 copies/mL) for at least one year, without any known history of treatment failure, on a 3-drug combination ART consisting of an anchor drug with a 2-drug nucleos(t)ide reverse transcriptase inhibitor (NRTI) backbone. There will be no exceptions to eligibility requirements at the time of randomisation. Questions about eligibility criteria should be addressed prior to attempting to randomise the participant. The eligibility criteria are the standards used to ensure that only medically appropriate patients are considered for this study. Patients not meeting the criteria should not join the study. For the safety of the patients, as well as to ensure that the results of this study can be useful for making treatment decisions regarding other patients with similar diseases, it is important that no exceptions be made to these criteria for admission to the trial. Participants will be considered eligible for enrolment in this trial if they fulfil all the inclusion criteria and none of the exclusion criteria as defined below. INCLUSION CRITERIA 1. HIV-1-positive 2. Aged 12-19 years 3. Aware of HIV status 4. Body weight ≥35Kg 5. On ART consisting of 2NRTI and a third agent 6. On ART for ≥1 year with no previous regimen change for treatment failure* 7. Virologically suppressed with all HIV-1 RNA viral loads <50copies/mL¥ in the last 12 months up to and including screening. Additionally, there must be one result <50copies/mL¥ at least 12 months prior to screening and the viral load at trial screening must be <50 copies/mL 8. Written informed consent provided by participant (if aged 18 to 19 years) and/or carer/legal guardian (if participant aged 12 to 17 years) as appropriate 9. Written informed assent in participants aged 12 to 17 years 10. Females who are sexually active must be willing to adhere to highly effective methods of contraception? EXCLUSION CRITERIA 1. Known HIV-2 positive 2. Females who are pregnant or breastfeeding 3. Females who plan to become pregnant during the trial follow-up or are sexually active and are unwilling to avoid pregnancy for the duration of the trial 4. Moderate or high-risk score on the Columbia-Suicide Severity Rating Scale 5. Hepatitis B SAg positive 6. ALT ≥3 x upper limit of normal 7. On treatment for active TB 8. Known contraindication to receipt of dolutegravir, cabotegravir, rilpivirine, emtricitabine/ lamivudine and any formulation of tenofovir 9. Participants determined by the investigator to have a high risk of seizure, including those with unstable or poorly controlled seizure disorder 10. Unwilling or contraindication to receiving injections 11. Contraindication to receiving injectable agents in the buttock area 12. Underlying medical condition (e.g. bleeding disorder; use of warfarin) that in the opinion of the investigator precludes participation 13. Previous randomisation in the BREATHER Plus trial University College London (UCL), UK and funded by the European and Developing Countries Clinical Trials Partnership Medical and Health Sciences Clinical Trial Non-degree Award
Victoria Nankabirwa
ID: UNCST-2021-R011871
 Relaxation Intervention to Improve Newborn Growth and Maternal Well-being
REFNo: HS6916ES

To examine the effect of the APRB on maternal outcomes such as stress, anxiety and depression.,To evaluate the effect of the adapted APRB on infant outcomes such as growth, feeding and adverse events.,To develop and adapt an audiorecording promoting relaxation during breastfeeding (APRB) for use among postpartum mothers Uganda.,
 Uganda 2026-01-19 15:24:38 2029-01-19 136 Adult women (18 years and above) and their infants.All sexes and tribes are eligible US National Institutes of Health Medical and Health Sciences Clinical Trial Non-degree Award
JOSELYN RWEBEMBERA
ID: UNCST-2021-R013915
 A Non-Inferiority Trial of Stopping Penicillin in Early Rheumatic Heart Disease: GOAL-Stop
REFNo: HS6744ES

To explore if risk of progression differs between children who initially received 2 years of oral SAP as compared to 2 years of intramuscular SAP during the GOALIE trial. ,To determine in children with previously diagnosed mild RHD and echocardiographic stabilization after receiving SAP for at least 2 years, if stopping secondary antibiotic prophylaxis (SAP) is non-inferior to continuing SAP in preventing progression over the next 2 years. ,To determine in children with previously diagnosed mild RHD and echocardiographic normalization after receiving SAP for at least 2 years, if stopping SAP is non-inferior to continuing SAP for preventing progression over the next 2 years. ,To determine in children with previously diagnosed mild RHD and echocardiographic normalization or echocardiographic stability after receiving SAP for at least 2 years, if stopping SAP is non-inferior to continuing SAP for preventing progression by 4 years (2 years after SAP discontinuation). ,
 Uganda 2025-12-18 18:47:07 2028-12-18 992 Children and adolescents will be eligible for study participation if they (1) participated in the GOALIE Trial, (2) are found to have echocardiographic normalization or stable mild RHD at study completion, (3) are between the ages of 5-20 years at the time of enrollment. Thrasher Research Fund & Open Philanthropy Medical and Health Sciences Clinical Trial Non-degree Award
Pauline Byakika-Kibwika
ID: UNCST-2019-R001206
 A phase III, multi-country, randomized, placebo-controlled, double-blinded adaptive platform trial to assess the efficacy and safety of treatments for participants with Mpox virus disease
REFNo: HS6913ES

To evaluate the safety and efficacy, as assessed by mortality, hospitalization, complications, duration of symptoms of IP + SOC compared to placebo + SOC in participants with Mpox.,The primary objective is to evaluate the clinical efficacy, as assessed by time to lesion(s) resolution, of IP + Standard of Care (SOC) compared to placebo + SOC for participants with Mpox.,
 Wakiso, kisubi
Mbarara, Mbarara
 Uganda 2025-12-18 18:34:19 2028-12-18 422 Participants fulfilling all the following inclusion criteria are eligible for the study: 1. Signed informed consent or assent for minor participants 2. Adults with positive mpox virus PCR confirmed within 7 days of D1and at least one skin lesion: - with known self-reported HIV positive with or without mucosal lesions - Or - Self-reported HIV negative or unknown HIV status with mucosal lesions 3. Children with positive mpox virus PCR confirmed within 7 days of D1 and at least one skin lesion 4. Newborns with positive mpox virus PCR confirmed within 7 days of D1 and at least one skin lesion 5. Specific to the BCV arm and matching placebo-Women participants of childbearing potential willing to use condoms during treatment and for at least 2 months after the last dose of BCV. 6. Specific to the BCV arm and matching placebo-Male participants with partners of childbearing potential willing to use condoms during treatment and for at least 4 months after the last dose of BCV. i. To protect women of a potential teratogenic treatment ii. and anyhow for MSM (men who have sex with men to avoid sexual transmission PANdemic Preparedness Platform for Health and Emerging Infections’ Response (PANTHER) Medical and Health Sciences Clinical Trial Non-degree Award
Nelson Sewankambo K
ID: UNCST-2020-R014578
 Evaluation of an Information Management and Communication System for Population-wide Point-of-Care Infant Sickle Cell Disease Screening (SIMCS)- A Cluster Randomized Trial
REFNo: HS6567ES

(ii) To evaluate the impact of the SCD SIMCS on access to screening and care and outcomes of children with SCD,
 Jinja, Kakindu
Iganga,
Mayuge,
Kayunga,
Uganda 2025-12-05 18:30:02 2028-12-05 60 Health centers Infants aged 4-6 months National Institutes of Health Medical and Health Sciences Clinical Trial Non-degree Award
Bruce Kirenga J
ID: UNCST-2019-R001460
 Safety, preliminary efficacy, and Pharmacokinetics of Herbal/Natural/ Traditional therapeutic products for the management of Diabetes Mellitus in Uganda.
REFNo: HS6530ES

Main Objective
1. To evaluate the safety, effectiveness and pharmacokinetics of 3 selected NDA- notified herbal/natural/traditional therapeutic products in Uganda, designated IMP1, IMP2, and IMP3.
2. To explore the experiences of innovators, researchers, implementers, and participants involved in this study on the innovation and scientific evaluation of natural therapeutics in Uganda.

Specific Objectives
1. To determine the efficacy of selected NDA-notified herbal/natural/traditional therapeutic products (IMP1, IMP2 and IMP3) used in the treatment of diabetes mellitus in adult patients in Uganda
2. 2. To assess the effect of the selected NDA-notified herbal/natural/traditional therapeutic products (IMP1, IMP2 and IMP3) on specific cardio-metabolic characteristics of adult patients with DM in Uganda.
3. To assess clinical and laboratory adverse events associated with selected NDA- notified herbal/natural/traditional therapeutic products, specifically IMP1, IMP2 and IMP3 in adult patients with DM in Uganda.
4. To investigate the pharmacokinetic profile(s) of NDA-notified herbal/natural/traditional therapeutic products (IMP1, IMP2 and IMP3) used in the management of DM.
5. To explore the experiences of innovators, researchers, implementers, and participants involved in this study on the innovation and scientific evaluation of herbal/natural/traditional therapeutics in Uganda.e the pharmacokinetic profile(s) of NDA-notified herbal/natural/traditional therapeutic products (IMP1, IMP2 and IMP3) used in the management of DM.

Uganda 2025-12-01 14:19:22 2028-12-01 424 Objective 1- 4 Persons with a new or known diagnosis of diabetes mellitus Objective 5 Personnel working in research programs, including: Investigators, Program managers, Clinical staff Innovators of herbal/natural/ traditional therapeutic products purposed for diabetes mellitus management. Objective 1-4 Adult (≥18 years) patients with recently diagnosed diabetes mellitus (diagnosis made in the preceding three months) Objective 5 Individuals who have worked with the CONAT program as investigators, program manager, or clinical staff for at least six months. Innovators of herbal/natural/ traditional products for diabetes mellitus whose product will be found during the survey. Government of Uganda-STI-OP Medical and Health Sciences Clinical Trial Non-degree Award
Sarah Wilker
ID: UNCST-2025-R019791
 One size fits all? Towards individual prediction of treatment success for posttraumatic stress disorder in post-conflict settings (TRAUMA-FIT)
REFNo: HS6712ES

Main Objective 1. to identify individual predictors of treatment response to two different treatments in survivors with PTSD in a post-conflict setting Specific Objectives 1. Investigate whether NET is, on average, more effective than PM+ for the treatment of PTSD 2. Identify predictors of optimal response in the two conditions, and thereby identify predictors of treatment success in a trauma-focused versus present-focused treatment 3. Investigate the explanatory role of socio-ecological factors in PTSD treatment response
 Gulu,
Germany 2025-11-26 14:28:24 2028-11-26 660 (1) Adults of Age between 18 and 65; men and women, Acholi tribe (2) Survivor of trauma related to the LRA conflict or ongoing violence in the post-conflict setting; and (3) Probable diagnosis of PTSD according to DSM-5 (PSSI-5). German Research Foundation Medical and Health Sciences Clinical Trial Degree Award
MALLON TUSUUBIRA
ID: UNCST-2025-R021850
 SURVEY ON PARATUBERCULOSIS IN SLAUGHTERED GOATS AT KAMPALA CITY ABATTIOR
REFNo: A654ES

General objective
To establish the prevalence of Mycobacterium avium subsp. paratuberculosis infection in goats
Specific Objectives
i. To determine the prevalence of the gross and microscopic lesions associated with paratuberculosis in the ileocecal junction and associated lymph nodes of goats slaughtered at Kampala city abattoir
ii. To establish the prevalence of Mycobacterium avium sub species paratuberculosis in suspected cases using polymerase chain reaction (PCR)

 Wakiso, Kampala
 Uganda 2025-11-21 14:36:09 2028-11-21 The sample size required will be calculated by using the formula of the estimation of prevalence in a population (Thrusfield et al., 2018). n = Z².p.(1-p)/d² Where: • n = sample size required • Z = Z-value (1.96 at a 95% confidence interval) • p = expected prevalence (According to standard epidemiologic practices 50% will be used since the prevalence is unknown). (Thrusfield, 2018; Dohoo et al,2009) • d = precision (5%) n = 1.96².0.5. (1-0.5)/0.05² = 384 The samples will be obtained from Kampala city Abattoir, a large goat slaughter house along the old Port Bell Road. The samples will be analysed in the histopathology research laboratory (CDL) and the pathology Laboratory, SVAR Makerere University. The study population will be goats that are brought to the abattoir for slaughter. The goats are from different parts of Uganda, with the majority coming from central and western Uganda. They will be offering a representative population to study the prevalence and incidence of paratuberculosis. The target population will be all the slaughtered goats at the abattoir during the study period. Self sponsored Agricultural Sciences Clinical Trial Degree Award
Martin Origa Jobson Ariel
ID: UNCST-2022-R010809
 Validation of cervical cancer screening methods in Uganda: The National Cancer Management and Capacity building Project in Uganda (CANCAP UG) experience.
REFNo: HS6635ES

To assess multiple screening methods: VIA, PAP smear, HPV, and colposcopy, plus or minus biopsy.,To evaluate the indicators of screening accuracy (sensitivity, specificity, positive predictive value, negative predictive value) of Visual Inspection with Acetic acid (VIA) test by comparing with the gold standard of disease status confirmed via histological results.,
 Mbarara, cities
Mbarara, cities
Kampala, mulago
Kampala, kisenyi
 Uganda 2025-11-21 14:33:45 2028-11-21 4000 All women, 25 years old meeting the inclusion criteria and attending the screening clinic at CANCAP sites uganda cancer insitute Medical and Health Sciences Clinical Trial Non-degree Award
Jackson Mukonzo
ID: UNCST-2021-R013916
 Safety of COVIDEX™ Therapy in adults: in Uganda: A randomized controlled open- label phase 1 clinical trial.
REFNo: HS6540ES

Overall aim
To validate the safety of COVIDEX™ therapy in adult Ugandans.

Specific objectives
Primary objective
To evaluate and document adverse events associated with COVIDEX™ among adults
in Uganda.

Secondary objective:
To determine the plasma concentration of berberine in adults receiving COVIDEX™ at
three different dose levels.
Kampala,
Uganda 2025-11-21 14:11:01 2028-11-21 72 Study participants shall be healthy adult volunteers of 18years and above JENA HERBALS LIMITED Medical and Health Sciences Clinical Trial Non-degree Award
Eugene Ruzagira
ID: UNCST-2023-R008282
 A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women
REFNo: HS6565ES

To evaluate the efficacy of MK-8527 qm compared to FTC/TDF qd for the prevention of HIV-1 infection as assessed by the incidence rate per year of adjudicated HIV-1 infections To evaluate the safety and tolerability of MK-8527 qm compared to FTC/TDF qd.
 Masaka, Masaka
 Uganda 2025-11-21 11:18:30 2028-11-21 150 This study includes participants of varying age, race, ethnicity, and sex, female at birth, Aged from 16 years to 30 years of age inclusive, at the time of providing the informed consent or assent and Is confirmed HIV-uninfected based on negative HIV-1/HIV-2 test results during screening. Merck Sharp & Dohme LLC Medical and Health Sciences Clinical Trial Non-degree Award
ERIC WOBUDEYA
ID: UNCST-2019-R001047
 Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV
REFNo: HS6555ES

Primary Objectives
Cohort 1 and Cohort 2
• To determine the weight-band dosing of RPT taken as part of the 1HP regimen by evaluating:
? PK RPT exposures among children with and without HIV
? Safety and tolerability of the 1HP regimen among children with HIV while receiving twice-daily DTG and children without HIV through 28 days of dosing
Cohort 2
• To evaluate the effect of RPT taken as part of the 1HP regimen on the PK of DTG
Secondary Objectives
Cohort 1 and Cohort 2
• To evaluate the effect of covariates including age, weight, sex, ethnicity, nutritional status, and HIV-1 status on the PK of RPT taken as part of the 1HP regimen
• To evaluate the safety of the 1HP regimen through 24 weeks of follow-up
• To evaluate the palatability and acceptability of the 1HP regimen
• To evaluate adherence to the 1HP regimen
Cohort 2
• To evaluate the safety and tolerability of twice-daily DTG through 42 days among children with HIV who are receiving 1HP
• To evaluate virologic control (less than 200 copies/mL) at Day 42 among children taking a DTG-based ARV treatment regimen co-administered with 1HP

Kampala, mulago
 Uganda 2025-11-04 12:59:17 2028-11-04 40 children living without HIV (Cohort 1) and children living with HIV (Cohort 2) at risk of TB disease who are less than 13 years of age. National Institute of Allergy and Infectious Diseases Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institute of Mental Health Medical and Health Sciences Clinical Trial Non-degree Award
Henry Mugerwa
ID: UNCST-2019-R000420
 A5402 An Open-Label, Randomized Controlled Trial of Pramipexole versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD with Mild Neurocognitive Disorder (MND) in Persons with HIV
REFNo: HS6604ES

1.2 Primary Objectives

1.2.1 To compare pramipexole to escitalopram in the treatment of MDD (and comorbid MDD with MND) based on the Beck Depression Inventory-II (BDI-II/BDI-2) total score [Beck 1996] from baseline to week 24.

1.2.2 To evaluate the safety of pramipexole and escitalopram in PWH having MDD (and comorbid MDD with MND) from baseline to week 24.

1.3 Secondary Objectives

1.3.1 To compare pramipexole to escitalopram in the treatment of MDD using MDD caseness, neurocognitive outcomes, and functional status from baseline to week 24.

1.3.2 To compare the depression, neurocognitive, and functional status outcomes in PWH with MDD alone and with comorbid MDD with MND treated with pramipexole versus escitalopram from baseline to week 24.

1.3.3 To compare the impact of pramipexole and escitalopram on all outcomes above by female versus male sex (assigned at birth) from baseline to week 24.

1.3.4 To determine the impact of pramipexole compared to escitalopram on the measure of HIV-1 RNA viral load in the peripheral blood.

1.4 Exploratory Objectives

1.4.1 To characterize associations between escitalopram trough concentrations and treatment efficacy (BDI-II/BDI-2 total score) as well as participant adverse events (adverse event frequency, severity, and discontinuation rates).

1.4.2 To characterize associations between escitalopram trough concentrations and genetic polymorphisms that affect metabolizing enzymes of escitalopram (known metabolizing enzymes include CYP2C19, CYP2D6, and CYP3A4).

1.4.3 To explore associations between cerebrospinal fluid (CSF) concentrations of escitalopram and BDI-II/BDI-2 total score.

1.4.4 To evaluate adverse events potentially related to drug interactions between antiretroviral therapy (ART) and escitalopram and pramipexole, respectively.

1.5 Substudy Objective

1.5.1 CSF Substudy

To compare the impact of pramipexole and escitalopram on biomarker outcomes in a CSF substudy of participants with MDD alone.

 Uganda 2025-10-29 16:04:25 2028-10-29 50 PWH having a diagnosis of MDD alone or with comorbid MDD and MND · ≥18 to ≤70 years old both male and female. People who understand English and Luganda because the site informed consent forms only in Luganda and English National Institute of Allergy and Infectious Diseases and CIPLA Medical and Health Sciences Clinical Trial Non-degree Award
Abel  Kakuru
ID: UNCST-2022-R009193
 Dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone for the prevention of febrile illnesses in children with sickle cell anemia: a double-blind randomized controlled trial
REFNo: HS6294ES

1.
To compare the incidence of all-cause febrile illness among children with sickle cell anemia randomized to receive monthly SP vs. monthly DP+SP.
2.
To compare the incidence of adverse events among children with sickle cell anemia randomised to receive monthly SP vs. monthly DP+SP.
3.
To compare the prevalence of markers of antimalarial resistance, including those associated with SP and DP resistance, among parasitemic children with sickle cell anemia randomized to receive monthly SP vs. monthly DP+SP.
 Busia, Selected parishes
 Uganda 2025-10-29 15:55:44 2028-10-29 232 children with sickle cell anemia Aged 2-10 years children with sickle cell anemia Thrasher Research Fund Medical and Health Sciences Clinical Trial Non-degree Award
Kyambadde Ronald
ID: UNCST-2025-R016678
 HIGH DOSE VS STANDARD DOSE CAFFEINE THERAPY FOR APNEA OF PREMATURITY: A RANDOMISED CONTROL TRIAL.
REFNo: HS5776ES

To compare the efficacy and safety of high-dose caffeine citrate (loading dose 40 mg/kg/day, and maintenance of 20mg/kg/day), versus standard dose (loading dose of 20 mg/kg/day, maintenance of 10mg/kg/day), in preventing the occurrence and reducing the frequency of apneas among preterm infants ? 34 weeks’ gestation with Apnea Of Prematurity in the first 7 days of life.


Specific Objectives

1. To determine the effect of high dose compared to standard dose of caffeine on the incidence of apnea of prematurity among preterm babies at St. Francis Hospital, Nsambya, and Uganda
Martyrs’ Hospital Lubaga.

2. To determine the side effects of high dose compared to standard dose caffeine in preterm infants.
 Kampala, Nsambya
Kampala, Lubaga
 Uganda 2025-10-21 9:08:50 2028-10-21 122 participants preterm babies born at the study sites during the study period with a New Ballard score ≤ 34 weeks no sponsorship Medical and Health Sciences Clinical Trial Degree Award
Flavia Matovu Kiweewa
ID: UNCST-2021-R013337
 A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women
REFNo: HS6666ES

To evaluate the efficacy of MK-8527 qm
compared to FTC/TDF qd for the
prevention of HIV-1 infection as assessed
by the incidence rate per year of adjudicated
HIV-1 infections.
Hypothesis: MK-8527 qm is superior to
FTC/TDF qd with respect to the hazard
ratio for HIV-1 infecti
 Mityana,
Kalangala,
Kampala,
Masaka,
Wakiso,
Uganda 2025-10-16 17:51:09 2028-10-16 Approximately 4580 participants 16 to 30 years of age Merck Sharp & Dohme LLC Medical and Health Sciences Clinical Trial Non-degree Award
Helen Byakwaga
ID: UNCST-2019-R001168
 A Phase III/IV factorial randomised double-blind trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin/ezetimibe versus pitavastatin, in patients with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk (Optimising metabolic management on integrase-based antiretroviral therapy – the OPTIMAR Study)
REFNo: HS5819ES

To assess the impact of pitavastatin vs. rosuvastatin/ezetimibe from baseline to 48 weeks on: fasting lipids, cardiovascular disease risk assessment measures; inflammatory biomarkers; and safety and tolerability,To assess the impact of dapagliflozin vs. placebo from baseline to 48 weeks on: intermediate markers of cardiovascular disease risk; cardiovascular disease risk assessment measures; clinical consequences of increased body weight; and safety and tolerability of dapagliflozin,To assess the impact of pitavastatin vs. rosuvastatin/ezetimibe on LDL concentration change from baseline to week 24,To assess the impact of dapagliflozin vs. placebo on absolute weight change from baseline to week 24,The overall objective of the study is to examine the impact of dapagliflozin vs. placebo on metabolic parameters in PWH with high metabolic risk who are on INSTI-based ART.,
 Kampala, Mulago I
 Uganda 2025-09-30 14:11:23 2028-09-30 30 at the Infectious Diseases Institute Kampala All adults aged 40-75 years, both female, all tribes will be included. The Kirby Institute Medical and Health Sciences Clinical Trial Non-degree Award
Joweria Nambooze
ID: UNCST-2019-R001118
 Effect of consumption of cape gooseberries on blood glucose control among patients with type 2 diabetes mellitus in Kampala, Uganda
REFNo: HS6017ES

To evaluate patient adherence to dietary interventions involving gooseberries,To compare change in glycated hemoglobin (HbA1c) levels among T2DM patients consuming gooseberries regularly as part of their diet with those following a regular diet. ,To assess the effect of regular consumption of gooseberries on fasting blood glucose levels in T2DM patients.,To evaluate the effect of cape gooseberries on blood glucose control among patients with T2DM in Kampala, Uganda.,
 Kampala, All parishes
 Uganda 2025-09-26 18:13:11 2028-09-26 200 The study will include adult patients with T2DM who attend the Saint (St) Francis Nsambya hospital diabetes clinic and the Mulago hospital diabetes clinic in Kampala. Convenience sampling will be used to select patients from these clinics who meet specific study criteria and are readily accessible. The two study sites will be purposively selected due to having established T2DM clinics, high patient volume, diverse population and proper patient records. However, the study participants will be randomly allocated to the study arms. Kyambogo University Medical and Health Sciences Clinical Trial Non-degree Award
Patrick Okema
ID: UNCST-2025-R019099
 Insulin storage in low resource settings, impact on the glycated hemoglobin.
REFNo: HS6078ES

To determine the modalities of insulin storage in children and adolescents with T1D in low resource settings and the effects on their Hemoglobin A1C (HbA1C) in northern Uganda
 Gulu, All parish
Amuru, All parish
Nwoya, All parish
Omoro, All parish
 Uganda 2025-09-26 18:07:55 2028-09-26 60 - 100 Children and young adolescent with Type1 diabetes registered and is receiving care at the Gulu Regional Referral Hospital under the age of 23 years Sonia Nabeta Foundation Medical and Health Sciences Clinical Trial Non-degree Award
Jef VanPuyenbroeck
ID: UNCST-2025-R017911
 Monitoring anthelmintic resistance in goats in Nwoya District, Uganda
REFNo: A617ES

Main objective:
To assess the efficacy of anthelmintics commonly used by goat farmers in Nwoya district.
Specific Objectives:
1. To determine the prevalence of GIN infesting goats in Nwoya district.
2. To determine nematode species infesting goats in Nwoya district, through coproculture and molecular speciation.
3. To compare the expenses to perform routine FECRT, with McMaster and Mini-FLOTAC, for monitoring anthelmintic resistance in Uganda.
4. To assess the efficiency of survey designs and fecal egg count methods to determine drug efficacy at a certain cost and endemicity.
 Nwoya, All
Nwoya, All
Nwoya, All
 Belgium 2025-09-26 18:06:25 2028-09-26 383 All goat herds, kept for livelihood purposes, in Nwoya District will be considered to be included in this study. Ghent University Agricultural Sciences Clinical Trial Degree Award
Adoke Yeka
ID: UNCST-2021-R004300
 An open-label, randomised, controlled, non-inferiority trial to compare the efficacy, safety and tolerability of a fixed dose Triple Artemisinin-based Combination Therapy (TACT) artemether-lumefantrine-amodiaquine versus first-line Artemisinin-based Combination Therapies (ACTs) for the treatment of uncomplicated Plasmodium falciparum malaria
REFNo: HS6344ES

To compare the efficacy of ALAQ vs AL and ALAQ vs ASAQ as defined by the 28-day PCR corrected adequate clinical and parasitological response (ACPR).
 Tororo, Selected parishes
Busia, Selected parishes
 Uganda 2025-09-26 17:41:17 2028-09-26 1680 Male or female Participants with acute uncomplicated P. falciparum malaria University of Oxford Medical and Health Sciences Clinical Trial Non-degree Award
Robert Ssekitoleko
ID: UNCST-2019-R001716
 A Feasibility and Safety Study of the KeySuite Laparoscopic Devices for Cancer Diagnosis in Uganda
REFNo: SIR493ES

1. To evaluate potential safety issues associated with the use of the KeyScope in patients with intra-abdominal cancers or suspected cancers .
2. To determine the clinical performance of the KeyScope in viewing tissue masses in the abdomen.
3. To determine the clinical performance of the KeyLoop in retraction of the abdominal wall during laparoscopic surgery
4. To determine the acceptability of KeySuite laparoscopic devices in aiding to obtain laparoscopic biopsies

Kampala, Mulago II
 Uganda 2025-09-26 17:12:49 2028-09-26 12 The study is targeting 12 adult patients with cancer advised for an intra-abdominal biopsy to be collected for confirmatory. The study will target patients aged between 18 and 60 years. National Institute of Health Engineering and Technology Clinical Trial Non-degree Award
View Sort By:

Our Partners